CP-724714 is primarily investigated for its potential applications in cancer treatment. It functions as a selective inhibitor of the HER2/neu receptor tyrosine kinase, which is often overexpressed in certain types of breast cancer and other malignancies. By targeting this receptor, CP-724714 aims to inhibit the signaling pathways that promote tumor growth and survival. This makes it a promising candidate for therapeutic use in HER2-positive cancers, particularly in cases where resistance to other HER2-targeted therapies has developed. Research continues to explore its efficacy, safety, and potential combination with other treatments to enhance its anticancer effects.